Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL1883912 | 1.00 | ACHE (0.37) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL1878322 | 1.00 | ACHE (0.37) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL27979089 | 1.00 | ACHE (0.37) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL22689858 | 1.00 | ACHE (0.37) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL2023167 | 1.00 | ACHE (0.37) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL27885548 | 1.00 | ACHE (0.37) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL6550021 | 0.96 | ACHE (0.39) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL303395 | 0.87 | — | — | |
| Trimethylammonium SCHEMBL25438207 | 0.87 | TSHR (0.50) | TSHRALDH1A1HSD17B10 | |
| Trimethylammonium SCHEMBL1263576 | 0.87 | TSHR (0.50) | TSHRALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6433026-B1 | — | — | None | — | — | US | disclosed |
| CN-102822126-A | Selective hydroconversion of normal paraffins using borosilicate ZSM-48 molecular sieves | CHEVRON USA INC | 2012-12-12 | — | — | CN | disclosed |
| CN-102596807-A | Method for making borosilicate zsm-48 molecular sieves | CHEVRON USA INC | 2012-07-18 | — | — | CN | disclosed |
| US-20090155201-A1 | Alkylated poly(allylamine) polymers and methods of use | GENZYME CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| US-7399821-B2 | Alkylated poly(allylamine) polymers and methods of use | GENZYME CORPORATION (US) | 2008-07-15 | — | — | US | disclosed |
| US-20070155950-A1 | Alkylated poly(allylamine) polymers and methods of use | MANDEVILLE W H III | 2007-07-05 | — | — | US | disclosed |
| US-6784254-B2 | PREVENTING REABSORPTION OF BILE ACIDS FROM THE INTESTINE, DECREASING LIPOPROTEIN CHOLESTEROL IN THE BLOODSTREAM, BY ORAL ADMINISTRATING A SEQUESTER AGENT, CROSSLINKED POLYALLYLAMINE; BETTER TASTE | GENZYME CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-20040014899-A1 | Process for removing bile salts from a patient and alkylated compositions therefor | GELTEX PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | US | disclosed |
| US-6605270-B1 | Removing iron from patient by orally administering therapeutically effective amount of polymer characterized by specified repeat unit, or heteropolymer thereof | GENZYME CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-6433026-B2 | BILE SEQUESTERING POLYMER COMPRISES A CROSSLINKED, ALKYLATED, CATIONIC POLYAMINE OR POLYALLYLAMINE HOMO- OR CO-POLYMER | GELTEX PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-6225355-B1 | TO REMOVE BILE SALTS | GELTEX PHARMACEUTICALS, INC. | 2001-05-01 | — | — | US | disclosed |
| US-6066678-A | Process for removing bile salts from a patient and alkylated compositions therefor | GELTEX PHARMACEUTICALS, INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-5981693-A | Process for removing bile salts from a patient and alkylated compositions therefor | GELTEX PHARMACEUTICALS, INC. (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0764174-B1 | PROCESS FOR REMOVING BILE SALTS FROM A PATIENT AND ALKYLATED COMPOSITIONS THEREFOR | GELTEX PHARMA INC (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5917007-A | Process for removing bile salts from a patient and alkylated compositions therefor | GELTEX PHARMACEUTICALS, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0909768-A2 | Process for removing bile salts from a patient and alkylated compositions therefor | GELTEX PHARMACEUTICALS, INC. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5693675-A | Alkylated amine polymers | GELTEX PHARMACEUTICALS INC. (US) | 1997-12-02 | — | — | US | disclosed |
| US-5679717-A | Method for removing bile salts from a patient with alkylated amine polymers | GELTEX PHARMACEUTICALS, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| EP-0764174-A1 | PROCESS FOR REMOVING BILE SALTS FROM A PATIENT AND ALKYLATED COMPOSITIONS THEREFOR | GELTEX PHARMACEUTICALS, INC. (US) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995034585-A1 | PROCESS FOR REMOVING BILE SALTS FROM A PATIENT AND ALKYLATED COMPOSITIONS THEREFOR | GELTEX PHARMACEUTICALS, INC. (US) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155201-A1 | Alkylated poly(allylamine) polymers and methods of use | ABCB11, SLC10A1, MGMT | ACHE 4644/4885TSHR 2614/4885ALDH1A1 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.